Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Phase 3 trials of CagriSema demonstrated: 15.6% body weight loss with the combination versus 8.1% with semaglutide alone Superior glycemic control compared to either component individually Manageable side effect profile with proper dose titration Regulatory submissions completed in 2024 for obesity treatment [6] Since retatrutide includes GLP-1 receptor activation (similar to semaglutide) plus additional GIP and glucagon receptor effects, the theoretical cagrilintide blend with retatrutide could potentially exceed even the impressive CagriSema results
The tirzepatide doses of 10 and/or 15 mg demonstrated superiority compared to placebo for the coprimary endpoints percentage body weight reductions from baseline at week 72 and the proportion of patients achieving 5% body weight reduction at week 72
Zydus Lifesciences has announced a licensing partnership with Lupin and Torrent Pharmaceuticals
Addressing these signs through early intervention offers a pathway to recovery and wellness, fostering positive transformations in an individuals life
